Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
6.98
-0.43 (-5.80%)
Jul 15, 2025, 4:00 PM - Market closed
Journey Medical Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Journey Medical stock has a target of 9, which predicts a 28.94% increase from the current stock price of 6.98.
Price Target: $9 (+28.94%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Sep 6, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for Journey Medical is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 3 | 3 | 3 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lake Street | Lake Street | Strong Buy Initiates $9 | Strong Buy | Initiates | $9 | +28.94% | Sep 6, 2024 |
| Roth MKM | Roth MKM | Strong Buy Initiates $11 | Strong Buy | Initiates | $11 | +57.59% | Jun 28, 2024 |
| Alliance Global Partners | Alliance Global Partners | Strong Buy Initiates $8.5 | Strong Buy | Initiates | $8.5 | +21.78% | Feb 16, 2024 |
| B. Riley Securities | B. Riley Securities | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | -14.04% | Sep 7, 2023 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $3 → $6 | Strong Buy | Maintains | $3 → $6 | -14.04% | Jul 12, 2023 |
Financial Forecast
Revenue This Year
72.41M
from 56.13M
Increased by 28.99%
Revenue Next Year
110.50M
from 72.41M
Increased by 52.61%
EPS This Year
-0.14
from -0.72
EPS Next Year
0.89
from -0.14
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 80.9M | 134.2M | 200.4M |
| Avg | 72.4M | 110.5M | 158.1M |
| Low | 62.6M | 84.3M | 116.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 44.0% | 85.3% | 81.4% |
| Avg | 29.0% | 52.6% | 43.1% |
| Low | 11.5% | 16.4% | 5.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.05 | 2.12 | 3.49 |
| Avg | -0.14 | 0.89 | 2.21 |
| Low | -0.31 | 0.25 | 1.00 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 290.6% |
| Avg | - | - | 148.0% |
| Low | - | - | 12.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.